VIENNA—Because harnessing the immune system is now proven as a way of managing breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes, according to Giuseppe Curigliano MD PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology, Milan—who presented an update of their role in mediating immune pathways in cancer at the St Gallen Breast Cancer Conference. He gave Oncology Times reporter Sarah Maxwell his insights into how the “immunome” could be used as a target.
You may also like...
Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer 27 Jan, 2008 Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer 27 Apr, 2015 PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer 6 Feb, 2014 PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer 6 Dec, 2016
- Previous story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- Next story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014